Diagnostic and Subdiagnostic Accumulation of Mast Cells in the Bone Marrow of Patients with Anaphylaxis: Monoclonal Mast Cell Activation Syndrome
The DOI matches its Crossref record; 39 of the 40 references it cites were found in a registry or an index.
Abstract
Background Patients with mastocytosis may suffer from severe hypotension after wasp or bee stings. In these patients, no specific IgE is detectable, but they usually have skin lesions and an elevated serum tryptase level. Methods We report on 6 patients who were referred to our department because of severe hypotension following bee or wasp stings without cutaneous lesions. Results In 3 patients, the baseline serum tryptase level was elevated (26, 36, and 67 ng/ml, respectively), and investigation of their bone marrow revealed systemic mastocytosis (SM). In the remaining 3 patients, serum tryptase levels were Conclusions All patients with unexplained hypotension after hymenoptera stings should undergo a thorough investigation for major and minor SM criteria regardless of the tryptase level or presence of skin lesions, in order to diagnose or exclude SM or a related subdiagnostic condition (1 or 2 minor SM criteria) tentatively termed monoclonal mast cell activation syndrome.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“These patients suffer from a combination of primary and secondary MCAS, and, as a result, they are at high risk to develop recurrent life-threatening anaphylaxis (21-23).”
From Proposed Diagnostic Algorithm for Patients with Suspected Mast Cell Activation Syndrome (2019) · cites this paper as [22]
In the citing paper
“in patients with systemic mastocytosis (SM) and MCAS, an IgE-dependent allergy (e.g., against insect venom) is frequently documented.”
From Proposed Diagnostic Algorithm for Patients with Suspected Mast Cell Activation Syndrome (2019) · cites this paper as [22]
In the citing paper
“These patients as well as those with cutaneous mastocytosis (CM) or SM are both classified as primary (clonal) MCAS (Table 2).”
From Proposed Diagnostic Algorithm for Patients with Suspected Mast Cell Activation Syndrome (2019) · cites this paper as [22]
Citations
Cites
Hsu, S. M., Raine, L., & Fanger, H. (1981) · Journal of Histochemistry & Cytochemistry · doi:10.1177/29.4.6166661 · Cited by 14,140
Hossfeld, D. K. (2002) · Annals of Oncology · doi:10.1093/annonc/mdf146 · Cited by 4,625
Diagnostic criteria and classification of mastocytosis: a consensus proposal
Valent, P., Horny, H.-P., Escribano, L., Longley, B. J., Li, C. Y., Schwartz, L. B., Marone, G., Nuñez, R., Akin, C., Sotlar, K., et al. (2001) · Leukemia Research · doi:10.1016/s0145-2126(01)00038-8 · Cited by 1,108 · cited 1×
“If at least one major and one minor or at least three minor SM criteria are fulfilled, the diagnosis SM is established [”
BackgroundSelf-citationNagata, H., Worobec, A. S., Oh, C. K., Chowdhury, B. A., Tannenbaum, S., Suzuki, Y., & Metcalfe, D. D. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.23.10560 · Cited by 872 · cited 1×
“In the vast majority of these patients, the bone marrow is affected. In most SM patients, the somatic KIT mutation 2468A→T (D816V) is detectable [”
BackgroundTryptase levels as an indicator of mast-cell activation in systemic anaphylaxis and mastocytosis
Schwartz, L. B., Metcalfe, D. D., Miller, J. S., Earl, H., & Sullivan, T. (1987) · New England Journal of Medicine · doi:10.1056/nejm198706253162603 · Cited by 784
Establishment of an immature mast cell line from a patient with mast cell leukemia
Butterfield, J. H., Weiler, D., Dewald, G., & Gleich, G. J. (1988) · Leukemia Research · doi:10.1016/0145-2126(88)90050-1 · Cited by 737 · cited 1×
“The human MC leukemia cell line HMC-1, known to display the KIT mutation D816V [”
BackgroundLongley, B. J., Tyrrell, L., Lu, S.-Z., Ma, Y.-S., Langley, K., Ding, T.-G., Duffy, T., Jacobs, P., Tang, L. H., & Modlin, I. (1996) · Nature Genetics · doi:10.1038/ng0396-312 · Cited by 607
Systemic Mast Cell Disease: ANALYSIS OF 58 CASES AND LITERATURE REVIEW
TRAVIS, W. D., LI, C.-Y., BERGSTRALH, E. J., YAM, L. T., & SWEE, R. G. (1988) · Medicine · doi:10.1097/00005792-198811000-00001 · Cited by 488
Schwartz, L. B., Sakai, K., Bradford, T. R., Ren, S., Zweiman, B., Worobec, A. S., & Metcalfe, D. D. (1995) · Journal of Clinical Investigation · doi:10.1172/jci118337 · Cited by 371
Classification and Diagnosis of Mastocytosis: Current Status
Metcalfe, D. D. (1991) · Journal of Investigative Dermatology · doi:10.1111/1523-1747.ep12468882 · Cited by 346
Research works printed but not linked: 3
- 10.1056%2fnejm199202273260912 · DOI
- 10.1016%2fs0091-6749%2897%2970314-2 · doi:10.1016/s0091-6749(97)70314-2 · Paper page
- 10.1159%2f000059404 · DOI · Paper page
Cited by
Items 101–132 of 132
Classification and Response Criteria in Mast Cell Disorders: Time to Revise?
Valent, P., & Horny, H. (2011) · International Archives of Allergy and Immunology · doi:10.1159/000320381 · Cited by 3
“and ISM presenting with small-sized mast cell infiltrates that are overlooked unless appropriate immunohistochemical and molecular tests are applied. A recently emerging issue is the relationship between SM and the so-called monoclonal mast cell activation syndrome, a condition defined by the presence of 1 or 2 minor…”
BackgroundSelf-citationMastocytosis and clonal mast cell activation syndrome
Górska, A., Niedoszytko, M., Lange, M., Jassem, E., & Roszkiewicz, J. (2011) · Cited by 3
Mast Cell Diseases and Drug Hypersensitivity Reactions
Bonadonna, P., Zanotti, R., VARANI, A. B., & Pagani, M. (2017) · Current Treatment Options in Allergy · doi:10.1007/s40521-017-0130-8 · Cited by 3
Ruëff, F., Mastnik, S., & Oppel, E. M. (2017) · Allergo Journal · doi:10.1007/s15007-017-1354-4 · Cited by 2
Sexual Dimorphism in Allergic and Mast Cell-Associated Diseases
Kotha, A., Maldonado, T. D., Hamze, H., Hussain, Z. Y., Gobinathan, N., Yao, A. Z., Abudulkadir, M., Ching, J. M., & Ryan, J. J. (2026) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-026-09150-w · Cited by 2
“The term “mast cell activation syndrome” was first used in a case report in 2007 [234] but patients with evidence of systemic mast cell degranulation in the absence of increased mast cell number were first discussed in 1991 [ 235].”
Ahmed, A., Paudel, B., & Sharma, A. (2026) · Digestive Diseases and Sciences · doi:10.1007/s10620-026-09958-8 · Cited by 2
Gülen, T., Elberink, J. N. G. O., & Brockow, K. (2019) · Springer eBooks · doi:10.1007/978-3-030-27820-5_9 · Cited by 2
Mast cells, mediators, and symptomatic activation
Bansal, A. S., Nicholas, A., Sumar, N., & Varney, V. (2024) · AIMS Allergy and Immunology · doi:10.3934/allergy.2024004 · Cited by 2
Mastocytosis as a risk factor for insect venom allergy
Bonadonna, P., Boni, E., & Zanotti, R. (2020) · Allergo Journal International · doi:10.1007/s40629-020-00120-y · Cited by 2
The Mast Cell Activation Syndrome: A Mini Review
Margaret, L. (2015) · MOJ Immunology · doi:10.15406/moji.2015.02.00032 · Cited by 2
“[12], who proposed that all MC disease is a manifestation of aberrant MC activation and should be designated as “mast cell activation disease” (MCAD) which described a full range of pathologic MC states.”
BackgroundLa previsión del futuro en la empresa
de Aizpuru, M. A. T. (1987) · Dialnet (Universidad de la Rioja) · Cited by 2
Venom immunotherapy in patients with mastocytosis
González‐de‐Olano, D., Álvarez‐Twöse, I., & Vega-Castro, A. (2020) · Allergo Journal International · doi:10.1007/s40629-020-00121-x · Cited by 2
Predictors of Clonality and Underlying Mastocytosis in Mast Cell Activation Syndromes
González‐de‐Olano, D., & Álvarez‐Twöse, I. (2024) · Current Allergy and Asthma Reports · doi:10.1007/s11882-023-01122-w · Cited by 1
Mast cell activation syndrome: The overdiagnosis problems
Mikryukova, N. V., & Калинина, Н. М. (2025) · Medical Immunology (Russia) · doi:10.15789/1563-0625-mca-3197 · Cited by 1
Chen, D., & George, T. I. (2018) · Elsevier eBooks · doi:10.1016/b978-0-323-47913-4.00020-3 · Cited by 1
Commentary: Managing clinician's assessment
Villar, S. S. (2009) · BMJ · doi:10.1136/bmj.b868 · Cited by 1
“To suspect anaphylaxis at Mrs Barroso’s presentation was difficult because she did not have symptoms such as urticaria, bronchospasm, or oedema. A subdiagnostic condition of mastocytosis, termed monoclonal mast cell activation syndrome, has been described recently and seems to be quite common.”
BackgroundRecommendations for Improving the Diagnostic Criteria for Mast Cell Activation Syndrome
Coleman, C. L. (2023) · Digital Access to Scholarship at Harvard (DASH) (Harvard University) · Cited by 1
Commentary: The value of complexity
Peile, E. (2009) · BMJ · doi:10.1136/bmj.b796
LIFE-THREATENING STINGS, BITES, AND MARINE ENVENOMATIONS
Elston, D. M. (2011) · Cambridge University Press eBooks · doi:10.1017/cbo9780511778339.015
Insect Sting Allergy and Mast Cell Disease
Bonadonna, P., Zanotti, R., & Ruëff, F. (2017) · Springer eBooks · doi:10.1007/978-3-319-46192-2_16
Mast cell activation disorder masquerading as a nervous breakdown
Nguyen, A. P., & Teuber, S. S. (2017) · Case Reports in Internal Medicine · doi:10.5430/crim.v4n3p51
“However, since its discovery there have been reported cases of MC-mediated symptoms with normal or only slightly elevated tryptase levels and without cutaneous evidence of mast cell disease, and not meeting the criteria for systemic mastocytosis on bone marrow evaluation.[6, 7] In 2010, Akin et al.”
BackgroundVenom Allergy and Management in Mastocytosis
Bonadonna, P., & Zanotti, R. (2019) · Springer eBooks · doi:10.1007/978-3-030-27820-5_10
Venom immunotherapy in patients with mastocytosis
González‐de‐Olano, D., Álvarez‐Twöse, I., & Vega-Castro, A. (2020) · Allergo Journal · doi:10.1007/s15007-020-2514-5
Prise en charge diagnostique et thérapeutique des syndromes d’activation mastocytaire
Clark, E., Schiffmann, A., Jentzer, A., Demoly, P. M., Guilpain, P., & Caimmi, D. P. (2021) · Revue française d'allergologie · doi:10.1016/j.reval.2021.09.002
(2007) · Current Opinion in Allergy and Clinical Immunology · doi:10.1097/aci.0b013e3282c4a534
Faculty Opinions recommendation of Mast cell activation syndrome: Proposed diagnostic criteria.
Asero, R. (2010) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.5967957.5967055
Mastocytosis as a risk factor for insect venom allergy
Bonadonna, P., Boni, E., & Zanotti, R. (2020) · Allergo Journal · doi:10.1007/s15007-020-2516-3
“These latter patients may have a limited, prediagnostic form of SM, also indicated as monoclonal mast cell activation syndrome (MMAS), but their risk of developing severe life-threatening anaphylaxis is similar to patients with SM [7,8,9].”
ResultChen, D., & George, T. I. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-10940-9.00021-6
Using Biologics in the Prevention of Anaphylaxis
Song, D. Y., Sood, A., Schworer, S. A., Iweala, O. I., & Kwan, M. (2025) · Current Allergy and Asthma Reports · doi:10.1007/s11882-025-01224-7
“In addition to an increased rate of anaphylaxis in ISM, individuals with monoclonal mast cell activation syndrome (MMAS), also have higher frequency of anaphylaxis [125–127].”
Christoforou, M. E., CAMPEN, L. C. M. C. V., Visser, F. C., Lee, C. K., Lemmon, S. L., Rowe, P. C., & Azola, A. M. (2026) · Cureus · doi:10.7759/cureus.102064
“Mast cell activation syndrome (MCAS) is a more recently recognized condition characterized by persistent, but episodic symptoms similar to allergic inflammation [8,9].”
Metadata
- Authors
- Sonneck, K., Florian, S., Müllauer, L., Wimazal, F., Födinger, M., Sperr, W. R., & Valent, P.
- Affiliations
- Medical University of Vienna (AT)
- Venue
- International Archives of Allergy and Immunology
- Publisher
- S. Karger AG
- Published
- 2006-10-20
- Volume
- 142
- Issue
- 2
- Pages
- 158-164
- ISSN
- 1018-2438 (ISSN-L)
- 1423-0097
- OpenAlex
- W2011616095
- Cited by
- 129
- References
- 40
- Citations by year
- 2026: 4 · 2025: 5 · 2024: 5 · 2023: 4 · 2022: 3 · 2021: 5 · 2020: 8 · 2019: 7 · 2018: 6 · 2017: 8 · 2016: 3 · 2015: 11 · 2014: 9 · 2013: 8 · 2012: 7
- FWCI
- 2.02
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.karger.com/Services/SiteLicenses (vor)
- www.karger.com/Services/SiteLicenses (tdm)
- Locations
- International Archives of Allergy and Immunology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Austrian Science Fund
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Mast cells and histamine
- Health Sciences › Medicine › Immunology and Allergy › Food Allergy and Anaphylaxis Research
- Health Sciences › Medicine › Rheumatology › Eosinophilic Disorders and Syndromes
- Keywords
- systemic mastocytosis, anaphylaxis, bee stings, wasp stings, hypotension, serum tryptase, bone marrow mast cells, mastocytosis diagnosis
- MeSH terms
- Anaphylaxis, Animals, Bees, Bone Marrow Cells, Female, Flow Cytometry, Humans, Hypotension, Immunohistochemistry, Insect Bites and Stings, Male, Mast Cells, Wasps, Mastocytosis, Systemic, Tryptases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.